Q-omics provides the consensus-scored PRDM12 profile across patient tissues and cancer cell-line models. PRDM12 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PRDM12 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, PRDM12 RNA expression shows 13,733 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRP as cancer lineages where PRDM12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDM12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDM12 survival associations across molecular data types. PRDM12 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDM12 RNA expression–survival associations across cancer types. High PRDM12 expression shows unfavorable associations in UVM, KIRC, HNSC, ACC, UCS and THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PRDM12 RNA expression.
This table summarizes PRDM12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRDM12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDM12 shows higher tumor expression in KIRP, COAD, LUAD, LIHC, BRCA and HNSC. The KIRP box plot shows higher PRDM12 RNA expression in tumor versus normal tissue (log2 FC = +0.537, t-test p < 0.001).
This table shows molecular features associated with PRDM12 in patient tissues and cancer cell lines. In patient samples, PRDM12 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRDM12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
